Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 2:57 am
Author: Getaka|Social: XLinkedIn

Gland Pharma Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹1,355.83Overvalued by 20.53%vs CMP ₹1,706.00

P/E (23.7) × ROE (11.6%) × BV (₹610.00) × DY (1.06%)

₹925.52Overvalued by 45.75%vs CMP ₹1,706.00
MoS: -84.3% (Negative)Confidence: 68/100 (Moderate)Models: All 9: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹1,345.3022%Over (-21.1%)
Graham NumberEarnings₹986.8816%Over (-42.2%)
Earnings PowerEarnings₹508.7713%Over (-70.2%)
DCFCash Flow₹766.1113%Over (-55.1%)
Net Asset ValueAssets₹610.007%Over (-64.2%)
EV/EBITDAEnterprise₹1,173.879%Over (-31.2%)
Earnings YieldEarnings₹709.607%Over (-58.4%)
ROCE CapitalReturns₹1,137.099%Over (-33.3%)
Revenue MultipleRevenue₹374.745%Over (-78%)
Consensus (9 models)₹925.52100%Overvalued

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -0.8%

*Investments are subject to market risks

Investment Snapshot

61
Gland Pharma Ltd scores 61/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health72/100 · Strong
ROCE 15.8% GoodROE 11.6% AverageD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money60/100 · Moderate
FII holding up 0.68% (6mo) Slight increasePromoter holding at 51.8% Stable
Earnings Quality55/100 · Moderate
OPM expanding (31% → 35%) ImprovingWorking capital: 249 days Capital intensive
Quarterly Momentum58/100 · Moderate
Revenue (4Q): 1% YoY FlatProfit (4Q): +4% YoY Positive
Industry Rank55/100 · Moderate
P/E 23.7 vs industry 53.8 Cheaper than peersROCE 15.8% vs industry 16.4% Average3Y sales CAGR: -2% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 2:57 am

Market Cap 28,107 Cr.
Current Price 1,706
Intrinsic Value₹925.52
High / Low 2,131/1,200
Stock P/E23.7
Book Value 610
Dividend Yield1.06 %
ROCE15.8 %
ROE11.6 %
Face Value 1.00
PEG Ratio-30.53

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Gland Pharma Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Gland Pharma Ltd 28,107 Cr. 1,706 2,131/1,20023.7 6101.06 %15.8 %11.6 % 1.00
J B Chemicals & Pharmaceuticals Ltd 32,253 Cr. 2,009 2,195/1,30342.8 2430.77 %25.8 %20.1 % 1.00
Pfizer Ltd 22,201 Cr. 4,853 5,993/3,70129.2 8410.72 %21.6 %16.4 % 10.0
Ajanta Pharma Ltd 35,192 Cr. 2,817 3,228/2,02234.7 3450.99 %32.4 %24.9 % 2.00
Wockhardt Ltd 20,598 Cr. 1,268 1,870/1,087190 2810.00 %3.75 %1.22 % 5.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Gland Pharma Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 9267858841,0111,0981,1751,0121,0631,0111,0301,0391,0741,178
Expenses 642616625664728742718699620636680699756
Operating Profit 284169259347369433294364391394359375422
OPM % 31%22%29%34%34%37%29%34%39%38%35%35%36%
Other Income 62-183541434748586544558336
Interest 32211510183740
Depreciation 38383940404341424443444545
Profit before tax 305112254347372433300380394391362409412
Tax % 25%29%26%26%26%26%26%26%25%26%26%26%25%
Net Profit 22879188258277321223282295290269302308
EPS in Rs 13.824.8111.3915.6416.8119.5113.5317.1017.9117.6016.3418.3318.69

Last Updated: February 5, 2026, 9:46 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 4:46 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 9919941,3481,4791,6202,0442,6333,4634,4013,6174,1674,1164,321
Expenses 6306788458541,0851,3381,6782,1612,8902,5982,7582,6742,771
Operating Profit 3613165026255357069551,3021,5111,0191,4101,4431,550
OPM % 36%32%37%42%33%35%36%38%34%28%34%35%36%
Other Income 93037344966139135224184166215217
Interest 131716644735782315
Depreciation 2857637478829599110147162169176
Profit before tax 3272724595785026869931,3351,6191,0481,4051,4661,575
Tax % 32%23%32%28%36%34%22%25%25%26%26%26%
Net Profit 2242093144143214527739971,2127761,0431,0901,169
EPS in Rs 190.40133.53202.40267.01207.24291.6549.8860.9473.7847.1163.3466.1470.96
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%32%27%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-6.70%50.24%31.85%-22.46%40.81%71.02%28.98%21.56%-35.97%34.41%4.51%
Change in YoY Net Profit Growth (%)0.00%56.94%-18.39%-54.31%63.27%30.21%-42.04%-7.41%-57.54%70.38%-29.90%

Gland Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:15%
5 Years:9%
3 Years:-2%
TTM:-4%
Compounded Profit Growth
10 Years:18%
5 Years:7%
3 Years:-3%
TTM:5%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:-8%
1 Year:0%
Return on Equity
10 Years:15%
5 Years:14%
3 Years:12%
Last Year:12%

Last Updated: September 5, 2025, 4:45 am

Balance Sheet

Last Updated: December 4, 2025, 1:17 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 12161516161616161616161616
Reserves 8221,3791,6622,0742,3952,8473,6315,8877,1427,9378,9799,73910,034
Borrowings 1761661176655554454
Other Liabilities 277197292378512655435588671815542661771
Total Liabilities 1,2871,7582,0862,4742,9283,5234,0866,4967,8348,7739,54110,42210,825
Fixed Assets 4606497888728439299689541,5021,5711,6941,7451,697
CWIP 2081922021611991231883381911771204253
Investments 0000000116382,3862,7903,293
Other Assets 6199171,0961,4411,8872,4712,9295,2035,9787,0175,3425,8455,783
Total Assets 1,2871,7582,0862,4742,9283,5234,0866,4967,8348,7739,54110,42210,825

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 2204762021857016057913681,1361,074
Cash from Investing Activity + -12-100-359-319-761-1,521-1,0071,211-2,9181,582
Cash from Financing Activity + -93-116-4-3-71,2383515-7-340
Net Cash Flow 115260-160-136-67322-1811,594-1,7892,316
Free Cash Flow 3336011750530377270145899962
CFO/OP 67%102%67%58%99%70%79%67%103%99%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow185.00150.00385.00619.00529.00701.00950.00-4.00-4.00-3.00-3.00-4.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 6262951031079083718987103101
Inventory Days 229283248271283388250312205421253265
Days Payable 7458601361611908297801285681
Cash Conversion Cycle 217288283239229289251286214381299284
Working Capital Days 100141155154185191161169168241224249
ROCE %39%22%28%30%22%27%30%28%25%15%17%16%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 57.86%57.86%57.86%57.86%57.86%51.83%51.83%51.83%51.83%51.83%51.83%51.83%
FIIs 4.33%2.80%4.91%4.05%3.59%6.88%4.48%5.04%6.90%7.39%7.90%7.58%
DIIs 23.23%23.38%22.45%24.17%25.23%32.83%35.37%34.80%33.27%32.86%32.63%32.99%
Public 14.59%15.97%14.78%13.93%13.32%8.46%8.33%8.33%8.00%7.93%7.63%7.62%
No. of Shareholders 1,50,5781,81,7471,61,6271,36,0211,22,3751,22,6651,22,3581,21,0751,13,7881,10,67197,15194,578

Shareholding Pattern Chart

No. of Shareholders

Gland Pharma Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
HDFC Mid Cap Fund 6,111,753 1.22 1128.65,860,1792026-02-23 02:59:314.29%
SBI Large & Midcap Fund 3,170,000 1.56 585.372,000,0002025-12-08 00:33:5958.5%
Mirae Asset Large & Midcap Fund 3,110,648 1.36 574.413,075,9982026-01-25 03:15:351.13%
ICICI Prudential India Opportunities Fund 3,012,666 1.58 556.322,767,5172026-02-23 01:21:598.86%
Nippon India Growth Mid Cap Fund 2,800,000 1.24 517.05N/AN/AN/A
Mirae Asset ELSS Tax Saver Fund 2,384,231 1.69 440.272,283,9272026-02-23 02:59:314.39%
Mirae Asset Large Cap Fund 2,012,542 0.92 371.642,105,8932026-02-23 01:16:54-4.43%
Nippon India Small Cap Fund 1,780,371 0.5 328.761,696,9332025-12-08 00:33:594.92%
Mirae Asset Midcap Fund 1,676,184 1.75 309.52N/AN/AN/A
Nippon India Multi Cap Fund 1,466,415 0.55 270.791,416,4372025-12-08 00:33:593.53%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) 42.4046.9047.4473.8163.07
Diluted EPS (Rs.) 42.4046.9047.4373.8162.99
Cash EPS (Rs.) 65.3367.8256.3380.4666.98
Book Value[Excl.RevalReserv]/Share (Rs.) 555.40529.65483.23435.64360.86
Book Value[Incl.RevalReserv]/Share (Rs.) 555.40529.65483.23435.64360.86
Revenue From Operations / Share (Rs.) 340.89343.92220.07267.85211.68
PBDIT / Share (Rs.) 89.9891.2776.82105.5487.84
PBIT / Share (Rs.) 67.0570.3567.9198.8381.80
PBT / Share (Rs.) 64.5068.7664.0398.5181.59
Net Profit / Share (Rs.) 42.4046.9047.4273.7560.94
NP After MI And SOA / Share (Rs.) 42.4046.9047.4273.7560.94
PBDIT Margin (%) 26.3926.5334.9039.4041.49
PBIT Margin (%) 19.6620.4530.8536.8938.64
PBT Margin (%) 18.9219.9929.0936.7738.54
Net Profit Margin (%) 12.4313.6321.5427.5328.79
NP After MI And SOA Margin (%) 12.4313.6321.5427.5328.79
Return on Networth / Equity (%) 7.638.859.8116.9216.88
Return on Capital Employeed (%) 11.4312.5013.8922.3922.36
Return On Assets (%) 6.227.248.8915.4615.34
Long Term Debt / Equity (X) 0.010.010.000.000.00
Total Debt / Equity (X) 0.020.030.000.000.00
Asset Turnover Ratio (%) 0.510.580.430.610.65
Current Ratio (X) 4.334.049.4610.0510.00
Quick Ratio (X) 3.262.856.808.027.51
Inventory Turnover Ratio (X) 3.361.251.101.661.72
Dividend Payout Ratio (NP) (%) 47.170.000.000.000.00
Dividend Payout Ratio (CP) (%) 30.610.000.000.000.00
Earning Retention Ratio (%) 52.830.000.000.000.00
Cash Earning Retention Ratio (%) 69.390.000.000.000.00
Interest Coverage Ratio (X) 35.3057.38169.90330.81421.28
Interest Coverage Ratio (Post Tax) (X) 17.6330.48113.46232.15293.28
Enterprise Value (Cr.) 23946.0928818.2817126.9950622.6337532.51
EV / Net Operating Revenue (X) 4.265.094.7311.5010.84
EV / EBITDA (X) 16.1519.1713.5429.1926.12
MarketCap / Net Operating Revenue (X) 4.675.365.7612.2111.71
Retention Ratios (%) 52.820.000.000.000.00
Price / BV (X) 2.873.482.637.506.87
Price / Net Operating Revenue (X) 4.675.365.7612.2111.71
EarningsYield 0.020.020.030.020.02

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Gland Pharma Ltd. is a Public Limited Listed company incorporated on 20/03/1978 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is L24239TG1978PLC002276 and registration number is 002276. Currently Company is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company's Total Operating Revenue is Rs. 4116.15 Cr. and Equity Capital is Rs. 16.48 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsSy.No. 143-148, 150 & 151, Hyderabad Telangana 500043Contact not found
Management
NamePosition Held
Mr. Srinivas SaduExecutive Chairman
Mr. Wenjie ZhangNon Exe.Non Ind.Director
Mr. Wei HuangNon Exe.Non Ind.Director
Dr. Jia Ai (Allen) ZhangNon Exe.Non Ind.Director
Mr. Essaji Goolam VahanvatiIndependent Director
Mr. Udo Johannes VetterIndependent Director
Mr. Satyanarayana Murthy ChavaliIndependent Director
Ms. Naina Lal KidwaiIndependent Director

FAQ

What is the intrinsic value of Gland Pharma Ltd and is it undervalued?

As of 14 April 2026, Gland Pharma Ltd's intrinsic value is ₹925.52, which is 45.75% lower than the current market price of ₹1,706.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (11.6 %), book value (₹610), dividend yield (1.06 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Gland Pharma Ltd?

Gland Pharma Ltd is trading at ₹1,706.00 as of 14 April 2026, with a FY2026-2027 high of ₹2,131 and low of ₹1,200. The stock is currently in the middle of its 52-week range. Market cap stands at ₹28,107 Cr..

How does Gland Pharma Ltd's P/E ratio compare to its industry?

Gland Pharma Ltd has a P/E ratio of 23.7, which is below the industry average of 53.84. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Gland Pharma Ltd financially healthy?

Key indicators for Gland Pharma Ltd: ROCE of 15.8 % indicates efficient capital utilization. Dividend yield is 1.06 %.

Is Gland Pharma Ltd profitable and how is the profit trend?

Gland Pharma Ltd reported a net profit of ₹1,090 Cr in Mar 2025 on revenue of ₹4,116 Cr. Compared to ₹1,212 Cr in Mar 2022, the net profit shows a declining trend.

Does Gland Pharma Ltd pay dividends?

Gland Pharma Ltd has a dividend yield of 1.06 % at the current price of ₹1,706.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Gland Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports